Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study
- PMID: 35777776
- PMCID: PMC10203882
- DOI: 10.1183/13993003.03173-2021
Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study
Abstract
Background: Hiatus hernia (HH) is prevalent in adults with pulmonary fibrosis. We hypothesised that HH would be associated with markers of lung inflammation and fibrosis among community-dwelling adults and stronger among MUC5B (rs35705950) risk allele carriers.
Methods: In the Multi-Ethnic Study of Atherosclerosis, HH was assessed from cardiac and full-lung computed tomography (CT) scans performed at Exam 1 (2000-2002, n=3342) and Exam 5 (2010-2012, n=3091), respectively. Percentage of high attenuation areas (HAAs; percentage of voxels with attenuation between -600 and -250 HU) was measured from cardiac and lung scans. Interstitial lung abnormalities (ILAs) were examined from Exam 5 scans (n=2380). Regression models were used to examine the associations of HH with HAAs, ILAs and serum matrix metalloproteinase-7 (MMP-7), and adjusted for age, sex, race/ethnicity, educational attainment, smoking, height, weight and scanner parameters for HAA analysis.
Results: HH detected from Exam 5 scans was associated with a mean percentage difference in HAAs of 2.23% (95% CI 0.57-3.93%) and an increase of 0.48% (95% CI 0.07-0.89%) per year, particularly in MUC5B risk allele carriers (p-value for interaction=0.02). HH was associated with ILAs among those <80 years of age (OR for ILAs 1.78, 95% CI 1.14-2.80) and higher serum MMP-7 level among smokers (p-value for smoking interaction=0.04).
Conclusions: HH was associated with more HAAs over time, particularly among MUC5B risk allele carriers, and ILAs in younger adults, and may be a risk factor in the early stages of interstitial lung disease.
Copyright ©The authors 2023. For reproduction rights and permissions contact permissions@ersnet.org.
Conflict of interest statement
Conflicts of interest: J.S. Kim reports a K23 grant from the National Heart, Lung, and Blood Institute related to the current study; is the recipient of a Pulmonary Fibrosis Foundation Scholar's Award; and has participated on a data safety monitoring board for a UVA Convalescent Plasma Trial. J. Kim has nothing to disclose. X. Yin has nothing to disclose. G.T. Hiura has nothing to disclose. M.R. Anderson reports a grant from the National Heart, Lung, and Blood Institute related to the current study. E.A. Hoffman reports National Institutes of Health grant funding to the University of Iowa, related to the current study; and is a founder and shareholder of VIDA Diagnostics, a company commercialising lung image analysis software developed, in part, at the University of Iowa. G. Raghu has nothing to disclose. I. Noth reports having received grants from the National Heart, Lung, and Blood Institute; and consulting fees from Boehringer Ingelheim, Genentech and Confo, in the 36 months prior to manuscript submission. A. Manichaikul reports a grant from the National Heart, Lung, and Blood Institute related to the current study. S.S. Rich has nothing to disclose. B.M. Smith reports National Institutes of Health grant R01-HL130506, paid to their institution related to the current study; and further grants to their institution from the National Institutes of Health, Canadian Institutes of Health Research and Fonds de Recherche du Québec, in the 36 months prior to manuscript submission. A.J. Podolanczuk reports a grant from the National Heart, Lung, and Blood Institute related to the current study; further grant funding from the American Lung Association; consulting fees from Regeneron, Boehringer Ingelheim, Imvaria and the National Association for Continuing Education; and participation on an ILD-related advisory board for Boehringer Ingelheim, all in the 36 months prior to manuscript submission. C.K. Garcia reports a grant from the National Heart, Lung, and Blood Institute related to the current study; as well as investigator-initiated research support from the Department of Defense and Boehringer Ingelheim; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Three Lakes Foundation and Stanford University, all in the 36 months prior to manuscript submission; as well as stock or stock options in Pliant Therapeutics; and a collaboration with AstraZeneca regarding genomic sequencing in 2020. R.G. Barr reports having received grants from the National Heart, Lung, and Blood Institute and the COPD Foundation. M.R. Prince has nothing to disclose. E.C. Oelsner has nothing to disclose.
Figures
Comment in
-
Limited interstitial abnormalities on CT associated with hiatus hernia: a pathogenetic pathway versus an epiphenomenon linked to biologic senescence.Eur Respir J. 2023 Jan 27;61(1):2201900. doi: 10.1183/13993003.01900-2022. Print 2023 Jan. Eur Respir J. 2023. PMID: 36707230 No abstract available.
References
-
- Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med 2020; 383: 958–968. - PubMed
-
- Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J 2012; 39: 344–351. - PubMed
-
- Tossier C, Dupin C, Plantier L, et al. Hiatal hernia on thoracic computed tomography in pulmonary fibrosis. Eur Respir J 2016; 48: 833–842. - PubMed
-
- Mackintosh JA, Desai SR, Adamali H, et al. In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality. Eur Respir J 2019; 53: 1802412. - PubMed
-
- Raghu G, Meyer KC. Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy? Eur Respir J 2012; 39: 242–245. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K23 HL140199/HL/NHLBI NIH HHS/United States
- HHSN268201500003C/HL/NHLBI NIH HHS/United States
- N01 HC095161/HL/NHLBI NIH HHS/United States
- N01 HC095168/HL/NHLBI NIH HHS/United States
- R01 HL077612/HL/NHLBI NIH HHS/United States
- N01 HC095159/HL/NHLBI NIH HHS/United States
- P30 DK063491/DK/NIDDK NIH HHS/United States
- UL1 TR001420/TR/NCATS NIH HHS/United States
- N01 HC095163/HL/NHLBI NIH HHS/United States
- HHSN268201500003I/HL/NHLBI NIH HHS/United States
- R01 HL130506/HL/NHLBI NIH HHS/United States
- UL1 TR000040/TR/NCATS NIH HHS/United States
- N01 HC095166/HL/NHLBI NIH HHS/United States
- N01 HC095160/HL/NHLBI NIH HHS/United States
- UL1 TR001079/TR/NCATS NIH HHS/United States
- N02 HL064278/HL/NHLBI NIH HHS/United States
- N01 HC095169/HL/NHLBI NIH HHS/United States
- P30 ES005605/ES/NIEHS NIH HHS/United States
- N01 HC095167/HL/NHLBI NIH HHS/United States
- RC1 HL100543/HL/NHLBI NIH HHS/United States
- R01 HL093081/HL/NHLBI NIH HHS/United States
- R01 HL130796/HL/NHLBI NIH HHS/United States
- N01 HC095162/HL/NHLBI NIH HHS/United States
- K23 HL150301/HL/NHLBI NIH HHS/United States
- R01 HL103676/HL/NHLBI NIH HHS/United States
- K23 HL130627/HL/NHLBI NIH HHS/United States
- UL1 TR001881/TR/NCATS NIH HHS/United States
- N01 HC095165/HL/NHLBI NIH HHS/United States
- N01 HC095164/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical